Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Non-Current Assets (2019 - 2025)

Immunocore Holdings' Non-Current Assets history spans 4 years, with the latest figure at $62.1 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 11.09% year-over-year to $62.1 million; the TTM value through Dec 2025 reached $62.1 million, up 11.09%, while the annual FY2025 figure was $62.1 million, 11.09% up from the prior year.
  • Non-Current Assets for Q4 2025 was $62.1 million at Immunocore Holdings, down from $79.7 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $80.1 million in Q2 2025 and bottomed at $52.8 million in Q4 2022.
  • The 4-year median for Non-Current Assets is $67.2 million (2024), against an average of $67.8 million.
  • The largest annual shift saw Non-Current Assets rose 0.9% in 2024 before it rose 20.42% in 2025.
  • A 4-year view of Non-Current Assets shows it stood at $52.8 million in 2022, then rose by 4.95% to $55.4 million in 2023, then increased by 0.9% to $55.9 million in 2024, then rose by 11.09% to $62.1 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Non-Current Assets are $62.1 million (Q4 2025), $79.7 million (Q3 2025), and $80.1 million (Q2 2025).